We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Part I. General subjects
-
1. Need for drug delivery systems 1
- Prof. Ana Catarina Silva
-
2. Need for drug delivery systems 2
- Prof. João Nuno Moreira
-
3. Routes of drug delivery
- Prof. Dr. Sven Stegemann
-
4. Transporters in drug delivery
- Dr. Pravin Shende
-
5. The theory and applications of controlled release principles
- Dr. Michael J. Rathbone
- Part II. Routes for drug delivery
-
6. Oral drug delivery
- Dr. Vineet Kumar Rai
-
7. Transdermal drug delivery
- Prof. Sabine Szunerits
-
8. Pulmonary drug delivery
- Prof. Anthony J. Hickey
-
9. Gastrointestinal drug delivery
- Prof. Susan Hua
-
10. Mucoadhesive drug delivery systems
- Dr. Panoraia I. Siafaka
-
11. Ocular drug delivery
- Prof. Emily Dosmar
-
12. Vaginal and uterine drug delivery
- Prof. José Luis Arias Mediano
-
13. Drug-eluting implants
- Dr. Aliasger K. Salem
- Part III. Materials for drug delivery
-
14. Polymers as nanocarriers for controlled drug delivery
- Prof. Dr. Marcelo Calderón
-
15. Polymeric gels for drug delivery
- Dr. G. Roshan Deen
- Ms. Dora Safar
-
16. Liposomes as a drug delivery system
- Dr. G. Roshan Deen
- Ms. Bushra Hasan
- Ms. Renad AlAnsari
-
17. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)
- Prof. Ana Catarina Silva
-
18. Micellar drug delivery
- Prof. Francesco Cellesi
-
19. Nanocrystals in drug delivery
- Prof. Eliana Souto
-
20. Layer-by-layer assemblies for drug delivery
- Prof. Szczepan Zapotoczny
-
21. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
22. Inorganic porous drug delivery carriers
- Prof. Jessica Rosenholm
- Part IV. Specifics of drug delivery
-
23. Delivery of genes and nucleotides
- Prof. Esam Yahya
-
24. Vaccine delivery
- Prof. Sevda Şenel
- Part V. Drug delivery in various diseases
-
25. Drug delivery for cancer therapeutics
- Prof. Tejraj Aminabhavi
-
26. Nanomedicines for brain diseases
- Prof. Giovanni Tosi
-
27. Drug delivery to the colon
- Prof. Susan Hua
-
28. Role of the lymphatic system in drug absorption
- Dr. Kishor M. Wasan
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Lymphatic transport: drug properties
- Characteristics of lymphatic drug transport
- Lymphatic transport
- Drug absorption in the lymph
- Mesenteric lymph duct
- Thoracic lymph duct
- Animal setup
- Case examples
- Amphotericin B (AmB)
- Oral AmB in mouse VL model
- Oral AmB ED50 in mouse VL model <2.5 mg/kg
- Antifungal activity
- Lymphatic transport of amphotericin B
- Pharmacokinetics: Ontazolast
- Effect of formulation
- Lymphatic transport of TG
- PRS-211,220 and Dexanabinol (1)
- PRS-211,220 and Dexanabinol (2)
- Effect of a high-fat meal on drug absorption (1)
- Effect of a high-fat meal on drug absorption (2)
- Intestinal lymphatic transport of drugs vs. degree of association with chylomicrons
- Characteristics of lymphatic drug transport
- Summary
- Thank you
Topics Covered
- The lymphatic system
- Lymphatic drug transport
- Amphotericin B lipid-based drug delivery
- Triglycerides and lymphatic transport
- Dexanabinol
- Diazepam
- Dichlorodiphenyltrichloroethane (DDT)
- High-fat meals and drug absorption
Talk Citation
Wasan, K.M. (2023, May 31). Role of the lymphatic system in drug absorption [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/AAVJ5507.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Kishor M. Wasan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Kishor Wasan.
I'm currently a Distinguished
University Scholar
and Adjunct Professor in
the Department of
Biological Sciences in
the Faculty of Medicine at the
University of British Columbia,
as well as the co-director
and co-founder
of our Neglected Global
Diseases Initiative.
I was a professor
at UBC and then was
a Dean of a pharmacy
school on the prairies,
retired from there
and have now come
back to my former university.
Today I'd like to
talk to you about
a very neat and niche area of
how we can enhance
the oral absorption of drugs
and its bioavailability.
0:34
The outline for my presentation
today is the following,
what is lymphatic transport?
What are the drug properties
required for
lymphatic transport?
What did become the
characteristics
of lymphatic transport?
Then I wanted to give you
some key actual examples
where drugs that are
your package into
lipid packages that
can enhance lymphatic
transport are done
or drugs themselves or nutrients
that had the
characteristics that make
them ideal for
lymphatic transport.
1:04
Over the years, a number of
different research groups
have worked together in
developing key principles and
properties that would
make a drug candidate,
a good candidate for
lymphatic transport.
Kind of like how we have
the Lipinski rule of five,
we've come down with
four fundamental
critical properties
that seemed to be
required in order for
a drug to be able to
absorb using the mechanisms
of lymphatic transport.
The first one is the cLog
P being greater than five,
that is the optimal
water coefficient.
The idea here is that a drug
that's very lipophilic,
water-loving in its properties
with greater of 5:1
ratio is something that
would be viable for
lymphatic transport.
The second is
triglyceride solubility.
That a drug has a
high solubility and
triglycerides usually greater
than 50 milligrams per mil,
and it's usually a function of
medium-chain triglycerides
and long-chain triglycerides.
A third factor is the ability of
the drug to partition
into chylomicrons.
Chylomicrons are
triglyceride-rich lipoproteins,
and usually anywhere between
40% distribution into
chylomicrons makes this an
ideal candidate for
lymphatic transport.
Finally, most drugs
usually have to be
small molecules and have
a molecular weight
less than 500.